• Immunic AG
  • Lochhamer Schlag 21
  • 82166 Gräfelfing
  • Germany
  • Phone: +49 (0)89 2080477 00
  • Fax: +49 (0)89 250079466
  • moc.xumi@ofni

Immunic (Nasdaq: IMUX) is a clinical-stage biotechnology company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. On August 2, 2020, Immunic announced positive top-line data from its phase 2 trial of IMU-838 in relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic.

4GENE ist einer der führenden Innovatoren in der Welt des erweiterten Kundenerlebnisses mit Geschmack und Duft. 4GENE entwickelt und produziert natürliche, biotechnologisch hergestellte, aktivierbare Aroma- und Duftstoffvorprodukte. Die Produkte werden als FLAVOUR-ON-DEMAND in den Bereichen Lebensmittel, Kosmetik und industrielle Anwendungen vermarktet.